Pharmacokinetic Study of TV-44749 Extended-release in Participants with Schizophrenia
- Study Title
- A Multi-center, Open-label, Randomized, Parallel-group Trial to Characterize the pharmacokinetics of three SC Olanzapine Extended-Release Formulations with Different Release Rates Following Single Administration in Participants with Schizophrenia or Schizoaffective Disorder
- Teva Identifier
- TV44749-NPC-10205
- ClinicalTrials.gov Identifier
- NCT06319170
- Study Status
- Completed
- Trial Condition(s)
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Drug: TV-44749
- Study Description
- The primary objective of the study is to characterize the pharmacokinetics of 3 formulations of olanzapine.
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years to 64 Years
- Trial Duration
- March 28, 2024 - January 15, 2025
- Phase
- Phase 1
